Tuesday, January 11, 2022 4:31:14 PM
1) The acquisition to continue to fuel growth
2) The 2022 outlook
https://ir.criver.com/static-files/f92d7468-bf01-4c5f-9bdb-7015940ab25a
Following the strategy, this looks good medium term/long term.
Best of luck in your investments!
Recent CRL News
- Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP • Business Wire • 05/02/2024 12:00:00 PM
- Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally • Business Wire • 04/22/2024 12:00:00 PM
- Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing • Business Wire • 04/16/2024 12:00:00 PM
- Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call • Business Wire • 04/12/2024 12:00:00 PM
- Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology • Business Wire • 04/11/2024 12:00:00 PM
- Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics • Business Wire • 04/09/2024 12:00:00 PM
- Charles River to Perform Plasmid Production for Ship of Theseus • Business Wire • 04/04/2024 12:00:00 PM
- Charles River to Perform Plasmid Production for Ship of Theseus • Business Wire • 04/04/2024 12:00:00 PM
- Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024 • Business Wire • 04/01/2024 12:00:00 PM
- Charles River Laboratories Publishes 2023 Corporate Citizenship Report • Business Wire • 03/27/2024 12:00:00 PM
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine • Business Wire • 03/21/2024 12:00:00 PM
- Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration • Business Wire • 03/14/2024 12:00:00 PM
- Charles River Laboratories to Present at Barclays Global Healthcare Conference • Business Wire • 03/12/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 08:42:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 07:34:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:54:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:09:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 05:47:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:37:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 08:14:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 05:42:07 PM
- Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use • PR Newswire (US) • 02/29/2024 07:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 09:57:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/22/2024 04:09:04 PM
- Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing • Business Wire • 02/21/2024 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM